Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results PR Newswire - Tue Apr 28, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market...

RIGL : 29.22 (-4.38%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Tue Apr 7, 7:05AM CDT

SOUTH SAN FRANCISCO, Calif. , April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals,...

RIGL : 29.22 (-4.38%)
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology PR Newswire - Tue Mar 31, 7:05AM CDT

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC

RIGL : 29.22 (-4.38%)
Rigel: Q4 Earnings Snapshot AP - Tue Mar 3, 3:18PM CST

Rigel: Q4 Earnings Snapshot

RIGL : 29.22 (-4.38%)
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update PR Newswire - Tue Mar 3, 3:01PM CST

SOUTH SAN FRANCISCO, Calif. , March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 29.22 (-4.38%)
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update PR Newswire - Tue Feb 24, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results...

RIGL : 29.22 (-4.38%)
Rigel Appoints Michael P. Miller to the Board of Directors PR Newswire - Tue Feb 3, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller...

RIGL : 29.22 (-4.38%)
Rigel Provides Business Update and 2026 Outlook PR Newswire - Mon Jan 12, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 29.22 (-4.38%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PR Newswire - Fri Jan 9, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 29.22 (-4.38%)
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire - Wed Jan 7, 7:05AM CST

SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 29.22 (-4.38%)

Barchart Exclusives

Coca-Cola Just Proved Blue-Chip, Dividend Stocks Aren't Boring as KO Stock Pops on 10% Revenue Growth Barchart - Wed Apr 29, 6:30PM CDT
Coca-Cola made “boring” blue chips look interesting again, with solid top-line growth, a rising stock, and steady strength quietly turning into market excitement. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.